STOCK MARKET BSE NSE

High Court Allows Merger of Ranbaxy, Sun Pharmacutical

Published: 10th March 2015 06:00 AM  |   Last Updated: 10th March 2015 03:37 AM   |  A+A-

HYDERABAD: The $4 billion Sun-Ranbaxy deal on Monday inched a step closer with the Punjab & Haryana High Court giving its approval for the merger.

With this, all the approvals are in place for Dilip Shanghvi-led Sun to complete the merger process and catapult itself into the world’s fifth-largest generic drug maker.

sun.jpgIt may be noted that the Competition Commission of India (CCI) had already given its conditional nod to the merger, asking both companies to divest seven drug assets in India. It is believed that process is already under way. Similarly, the US Federal Trade Commission, too, cleared the proposal in January.

“Ranbaxy Laboratories has informed BSE that the Punjab & Haryana High Court has orally pronounced the order on March 9, 2015, approving the Scheme of Arrangement involving the merger of Ranbaxy Laboratories Ltd with Sun Pharmaceutical Industries Ltd, under Sections 391 to 394, Sections 78 and 100 of the Companies Act, 1956, and Section 52 of the Companies Act, 2013,” Ranbaxy said in a disclosure with the bourses.

While giving its nod, the CCI had asked Sun Pharma to divest all products containing tamsulosin and tolterodine, currently marketed and supplied under the Tamlet brand, while Ranbaxy was asked to divest the brands Terlibax, Rosuvas EZ, Raciper L, Terlibax, Triolvance, Olanex F.

The all-share deal, considered as the largest in the Asia-Pacific region’s pharmaceutical sector, announced last year, is seen as a rare purchase of a local rival by a leading Indian company.

The buyout is valued at $4 billion including Ranbaxy’s debt of about $800 million, which will be passed on to Sun.

In 2008, Japan’s Daiichi Sankyo had acquired a 63.9 per cent stake in Ranbaxy for $4.2 billion.

But the value of its investment eroded significantly, as Daiichi couldn’t ensure compliance with norms at Ranbaxy’s factories supplying drugs to the US.

More from Business.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp